Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Identify the lowest expense ratio among dividend etfs quickly and compare key funds side by side to guide your next investment move.
27,594 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Nvidia's surge in AI chips is reshaping markets, and some analysts frame it as a $200 billion warning for rivals like...
A veteran hedge-fund manager behind an early SpaceX investment argues the AI-driven bottleneck trade is fading, trigg...
A kitchen-renovation boom masks a hidden health hazard for fabricators. This report outlines how your quartz countert...
Both Tesla and Rivian have slipped about 12% this year. This article cuts through the market noise to evaluate fundam...
Nvidia stands at a crossroads as it prepares to report Feb earnings. This article unpacks why the result could redefi...
As stocks march unfolds, the electric vehicle sector presents both challenges and opportunities. Here are two underva...
Investors chase the next big AI champion. This piece breaks down how a single AI stock could grow into a trillion-dol...
As AI accelerates, blue-collar automation could reshape factory floors. This piece examines which robotics stocks sta...
Cathie Wood’s approach to downturns leans into disciplined bargain hunting. This article breaks down the idea of cath...
Arthur Hayes liquidated his entire Zcash position after a publicly disclosed Orchard Pool vulnerability. The move und...
Optics stocks rally as AI infrastructure demand returns, led by Applied Optoelectronics with notable moves in LUMENTU...